Navigation Links
DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
Date:3/7/2013

083 represents a 'first in class' small-molecule chemotherapeutic. VAL-083 has been assessed in multiple NCI-sponsored clinical studies in various cancers including lung, brain, cervical, ovarian tumors and leukemia.  Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.  VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer

Based on published research, the mechanism of action of VAL-083 is understood to be a bi-functional alkylating agent; however, the functional groups associated with alkylating events has been shown to differ from other alkylating agents used in the treatment of GBM.

VAL-083 has previously demonstrated activity in cyclophosphamide, BCNU and phenylanine mustard resistant cell lines and no evidence of cross-resistance has been encountered in published clinical studies.  Based on the presumed alkylating functionality of VAL-083, published literature suggests that DNA repair mechanisms associated with Temodar and nitrosourea resistance, such as 06-methylguanine methyltransferace (MGMT), may not confer resistance to VAL-083. 

VAL-083 readily crosses the blood brain barrier where it maintains a long half-life in comparison to the plasma.  Published preclinical and clinical research demonstrates that VAL-083 is selective for brain tumor tissue.

VAL-083 has been assessed in multiple studies as chemotherapy in the treatment of newly diagnosed and recurrent brain tumors.  In general, tumor regression was achieved following therapy in greater than 40% of patients treated and stabilization was achieved in an additional 20% - 30%.  In published clinical studies, VAL-083 has previously been shown to have a statistically significant impact on median survival in high grade gliomas when combined with radiation vs. radiation alone. 

The mai
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
2. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
4. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
5. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
6. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
7. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
8. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
9. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
10. Cylene Pharmaceuticals and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
11. Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the Phase II proof of concept clinical study ... a monotherapy in the treatment of chronic pruritus ... significant and clinically meaningful improvement from baseline by ... on a 100mm unit Visual Analog Scale (VAS) ...
(Date:3/4/2015)... NEW YORK , March 4, 2015 /PRNewswire/ ... orthopedic device market is the increasing elderly population, ... in a recent report from the healthcare market ... aging population coupled with other risk factors such ... orthopedic incidence worldwide. Demand for innovative product designs ...
(Date:3/4/2015)... BEIJING, March 4, 2015 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in China, today ... fiscal year 2014. Fourth Quarter 2014 ... fourth quarter of 2014 increased by 36.2%, or 36.8% ... to $58.0 million from $42.6 million in the same ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22
... OAKLAND, Calif., Jan. 19, 2012  Kaiser Permanente, committed to ... announced today it is converting its IV medical equipment ... and DEHP, two industrial chemicals used in plastics that ... Kaiser Permanente has agreed to purchase IV ...
... 19, 2012  BioElectronics Corporation. (OTC-PINK: BIEL), the maker of ... announced the acceptance for publication of an article in ... of Foot and Ankle Surgery. The article documents ... medical device on plantar fasciitis. Plantar fasciitis, ...
Cached Medicine Technology:Kaiser Permanente Moves to Green Medical Supplies by Converting to Eco-Friendly IV Equipment 2Kaiser Permanente Moves to Green Medical Supplies by Converting to Eco-Friendly IV Equipment 3BioElectronics' Study on Plantar Fasciitis to be Published in The Journal of Foot and Ankle Surgery 2
(Date:3/4/2015)... Ultraman Florida is a grueling extreme ... mile bike, and 52.4 mile run. Christian Isakson finished ... , "This race was awesome and tough," Isakson said. ... sponsors for supporting me through every part of this ... total of 40 select participants invited from across the ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 When people talk ... the top artists spread across numerous genres, the Houston ... the conversation. Each night during the annual livestock show and ... addition to the other activities being held at the event. ... groups of performers that will try and get the festival ...
(Date:3/4/2015)... March 04, 2015 Dr. Christopher Asandra, ... Medical Center today lamented the FDA’s recent decision ... (TRT). He argued that FDA’s conclusions are not ... men who suffer from testosterone deficiency. , “The FDA ... on testosterone replacement therapy,” said Dr. Asandra. “There is ...
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... 04, 2015 TROY Healthcare Solutions will ... provides the ultimate level of security for prescriptions, in ... Houston Plaza Medical Center located at 6633 Travis Street ... at 7 AM, TROY Healthcare Solutions will host a ... will offer brief presentations each hour to introduce attendees ...
Breaking Medicine News(10 mins):Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3
... ... , ... (PRWEB) June 16, 2010 -- Enovate , a leading provider of mobile and ... European, Middle-Eastern, Pacific-Rim, and South American healthcare markets. Similar to the United States, the ...
... ... laser lipolysis competitors by empowering its patients with education about liposuction and body sculpting procedures, ... ... Soluna MD is its commitment to patient education. The Soluna MD staff, led by general ...
... ... than their actual weight. , , ... Ontario, Canada (PRWEB) June 16, 2010 -- The Quantum Scale is a personal weight loss ... target or ideal weight. Upon initial use, the scale registers (but does not display) the actual ...
... that causes chickenpox and shingles could lead to improved vaccines ... University of Edinburgh devised a technique to separate the virus ... a biochip, before incubating the chip with blood from people ... to pinpoint which proteins in the virus triggered a reaction ...
... ... found that untreated tooth decay in mothers almost doubled the odds of tooth decay in ... children, the authors say. , ... (Vocus) June 15, 2010 -- A UCSF study examining the oral health of rural Hispanic ...
... outcomes, many patients newly-diagnosed with early-stage lung cancer do ... factors associated with this decision include misunderstandings of the ... with black patients more likely to not have surgery, ... of JAMA . Lung cancer is ...
Cached Medicine News:Health News:Enovate Announces Global Expansion 2Health News:Miami's Soluna MD Educates Patients, Gains International Reputation for Excellence in Laser Lipo plus Ultrasound Technique, SmartLipo™ Ultra 2Health News:Miami's Soluna MD Educates Patients, Gains International Reputation for Excellence in Laser Lipo plus Ultrasound Technique, SmartLipo™ Ultra 3Health News:Revolutionary scale makes losing weight easier than ever 2Health News:If Mother Has Tooth Decay, Odds Increase That Child Does Too 2Health News:If Mother Has Tooth Decay, Odds Increase That Child Does Too 3Health News:Study examines reasons patients with early stage lung cancer do not have surgery 2Health News:Study examines reasons patients with early stage lung cancer do not have surgery 3
Topics include: ECG reading, ACLS (all the latest protocols and pearls), CHF, acute MI, cardiac testing, palpitations, pericarditis, arrhythmias, murmurs, athletes, valvular disease, endocarditis, sy...
Cardiology Core Curriculum fills the gap between the preclinical pathophysiology texts and specialist volumes aimed at cardiologists. It covers clinical cardiology for medical students, cardiology tr...
... published by Unbound Medicine ... resource that combines evidence-based ... edge technology. It offers ... specifically engineered to provide ...
This electronic survival guide provides all the essential information that every surgery intern needs from Day 1 on the wards....
Medicine Products: